WASL

Across TCGA pan-cancer cohorts, WASL mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated WASL data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher WASL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated WASL expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where WASL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.963	0.673	.004	32	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	18	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
GBM	OS	Median	All	0.584	0.923	.006	3	view →
LSCC	OS	Median	III,IV	0.664	0.996	.015	3	view →
UCEC	DFS	Median	All	0.960	0.849	.024	2	view →
CCRCC	OS	Median	All	0.983	0.907	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

WASL–HNSC (DFS)

Open the HNSC breakdown →